Bottom Line: Children and young adults who start antidepressant therapy at high doses, rather than the “modal” [average or typical] prescribed doses, appear to be at greater risk for suicidal behavior during the first 90 days of treatment.

Author: Matthew Miller, M.D., Sc.D., of the Harvard School of Public Health, Boston, and colleagues.

Background: A previous meta-analysis by the U.S. Food and Drug Administration (FDA) of antidepressant trials suggested that children who received antidepressants had twice the rate of suicidal ideation and behavior than children who were given a placebo. The authors of the current study sought to examine suicidal behavior and antidepressant dose, and whether risk depended on a patient’s age.

How the Study Was Conducted: The study used data from 162,625 people (between the ages of 10 to 64 years) with depression who started antidepressant treatment with a selective serotonin reuptake inhibitor at modal (the most prescribed doses on average) or at higher than modal doses from 1998 through 2010.

Results: The rate of suicidal behavior (deliberate self-harm or DSH) among children and adults (24 years or younger) who started antidepressant therapy at high doses was about twice as high compared with a matched group of patients who received generally prescribed doses. The authors suggest this corresponds to about one additional event of DSH for every 150 patients treated with high-dose therapy. For adults 25 to 64 years old, the difference in risk for suicidal behavior was null. The study does not address why higher doses might lead to higher suicide risk.

Discussion: “Considered in light of recent meta-analyses concluding that the efficacy of antidepressant therapy for youth seems to be modest, and separate evidence that dose is generally unrelated to the therapeutic efficacy of antidepressants, our findings offer clinicians an additional incentive to avoid initiating pharmacotherapy at high-therapeutic doses and to monitor all patients starting antidepressants, especially youth, for several months and regardless of history of DSH.”

(JAMA Intern Med. Published online April 28, 2014. doi:10.1001/jamainternmed.2014.1053. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor’s Note: Authors made a conflict of interest and funding disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

In a related commentary, David A. Brent, M.D., of the University of Pittsburgh, and Robert Gibbons, Ph.D., of the University of Chicago, write: “In summary Miller et al are to be commended on a thoughtful and careful analysis of the effects of initiating antidepressants at higher than modal doses.”

“Their findings suggest that higher than modal initial dosing leads to an increased risk for DSH and adds further support to current clinical recommendations to begin treatment with lower antidepressant doses. While initiation at higher than modal doses of antidepressants may be deleterious, this study does not address the effect of dose escalation,” they continue.

“Moreover, while definitive studies on the impact of dose escalation in the face of nonresponse remain to be done, there are promising studies that suggest in certain subgroups, dose escalation can be of benefit. Finally it should be noted that in this study, there was no pre-exposure to post-exposure increase in suicidal behavior after the initiation of antidepressants in youth treated at the modal dosage,” they conclude.

(JAMA Intern Med. Published online April 28, 2014. doi:10.1001/jamainternmed.2013.14016. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor’s Note: Authors made conflict of interest and funding disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Sign In

Special News Release >

FOR IMMEDIATE RELEASE – FEBRUARY 12, 2015 CHICAGO – The JAMA Network launched its new journal, JAMA Oncology, today with a robust collection of articles reporting on new research, opinion and reviews. The featured research included: “Hereditary Diffuse Gastric Cancer Syndrome,…

Special News Release >

The weekly JAMA Report is now available at http://jama.newsmarket.com/. Every Tuesday at 11 a.m. Eastern time, a new JAMA Report will be posted. The JAMA Report is a weekly video and audio new release highlighting a study appearing in the…

Special News Release >

The JAMA Network journals have recently published several articles on breast cancer. Here are the news release headlines, with links to the releases, studies, and JAMA Report videos: JAMA: Many Breast Cancer Surgery Patients Do Not Receive Shorter, Less…

Special News Release >

The JAMA Network journals have recently published articles on telemedicine. Here are the news release headlines, with links to the releases, studies, a JAMA Report video for one article and an author podcast for another: JAMA Psychiatry: Telemedicine Collaborative Care…

Special News Release >

JAMA has recently published several articles on sickle cell disease. Here are the news release headlines, with links to the releases, studies, and JAMA Report video for two articles: Sickle Cell Trait Among African Americans Associated With Increased Risk…

Special News Release >

FOR IMMEDIATE RELEASE – November 3, 2014 CHICAGO – John S. Rhee, M.D., M.P.H., a professor and chairman of the department of otolaryngology and communication sciences at the Medical College of Wisconsin (MCW) in Milwaukee, has been named the next…

Special News Release >

FOR IMMEDIATE RELEASE – SEPTEMBER 22, 2014 CHICAGO – The JAMA Network will launch a new journal, JAMA Oncology, to publish important cancer-related research and named Mary L. (Nora) Disis, M.D., a professor of medicine at the University of Washington,…

Special News Release >

FOR IMMEDIATE RELEASE – SEPTEMBER 8, 2014 CHICAGO – Stephan Heckers, M.D., M.Sc., chair of the psychiatry department at Vanderbilt University in Nashville, Tenn., has been named the next editor-in-chief of JAMA Psychiatry, one of nine specialty journals in the…

Special News Release >

FOR IMMEDIATE RELEASE – AUGUST 29,2014 CHICAGO – Melina R. Kibbe, M.D., professor of surgery and vice chair of research in the department of surgery at Northwestern University Feinberg School of Medicine, has been named the next editor-in-chief of JAMA…

Special News Release >

JAMA has a new series of articles, the JAMA Guide to Statistics and Methods. These articles will provide explanations about statistical analytic approaches and methods used in research reported in JAMA articles, to help readers better understand clinical research reports. These…